Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· April 24, 2026

Economist Justin Wolfers Says Trump Policies Are 'Hurting The American People And He Doesn't Want To Admit It,' Instead Calling It 'Fake Inflation'

View original at finance.yahoo.com
Economist Justin Wolfers Says Trump Policies Are 'Hurting The American People And He Doesn't Want To Admit It,' Instead Calling It 'Fake Inflation' Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Expensive energy could persist for years without conflict resolution

    60% confidence
  • Oil prices are well below worst-case predictions of $250-$300 per barrel, currently around $90

    60% confidence
  • Current inflation is 'fake inflation' because of fuel and energy prices

    60% confidence
  • Without a satisfactory resolution to the conflict, energy price concerns will remain long-term

    60% confidence
  • Inflation fears are overblown

    60% confidence
  • Cost pressures Americans are feeling are very real, not fake

    60% confidence
  • Gas prices are really expensive right now and unavoidably noticeable

    60% confidence
  • Trump's policies are hurting the American people and he doesn't want to admit it

    60% confidence
  • Market uncertainty is reflected in both current oil prices and long-term expectations

    60% confidence
  • Americans will be 'very impressed' by what happens over the next week or so

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com